Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2019 Feb 7;53(2):1802187.
doi: 10.1183/13993003.02187-2018. Print 2019 Feb.

Randomised controlled trials in severe asthma: selection by phenotype or stereotype

Laurie Pahus  1   2   3 , Dany Jaffuel  4   5   6 , Isabelle Vachier  4 , Arnaud Bourdin  4   5   7 , Carey Meredith Suehs  4 , Nicolas Molinari  8 , Pascal Chanez  1   3
Affiliations
Free article
Comment

Randomised controlled trials in severe asthma: selection by phenotype or stereotype

Laurie Pahus et al. Eur Respir J. .
Free article
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: L. Pahus has nothing to disclose. Conflict of interest: D. Jaffuel has nothing to disclose. Conflict of interest: I. Vachier has nothing to disclose. Conflict of interest: A. Bourdin has been an investigator in clinical trials for and received grants, personal fees and non-financial support from GSK, has been an investigator in clinical trials for and received grants and personal fees from AstraZeneca, Boehringer Ingelheim, Novartis, Chiesi Farma and Teva, has been an investigator in clinical trials for PneumRx, has been an investigator in clinical trials for and received personal fees from Actelion, and received grants from Merck, outside the submitted work. Conflict of interest: C.M. Suehs has nothing to disclose. Conflict of interest: N. Molinari has nothing to disclose. Conflict of interest: P. Chanez reports grants and personal fees for consultancy, advisory board work and lectures from Almirall, Boehringer Ingelheim, Centocor, GSK, AstraZeneca, Novartis, Teva, Chiesi, ALK and Boston Scientific, and grants from AMU, outside the submitted work.

Comment on

Substances